Table 1.
Baseline Characteristics of the ARIC Cohort Study at Visit 4 (n=9556)
| NT‐proBNP <68.2 pg/mL | NT‐proBNP ≥68.2 pg/mL | |||
|---|---|---|---|---|
| BMI <30 | BMI ≥30 | BMI <30 | BMI ≥30 | |
| Participants, % | 32.1 | 19.3 | 33.2 | 15.4 |
| Clinical variables | ||||
| Age, ya | 61.6 (5) | 61 (5.1) | 64.2 (5.7) | 63.5 (5.5) |
| Female, n (%) | 1364 (44.4) | 1018 (55.3) | 2088 (65.9) | 1022 (69.3) |
| Black, n (%) | 669 (21.8) | 627 (34.1) | 378 (11.9) | 327 (22.2) |
| BMI, kg/m2 a | 26.1 (2.6) | 34.6 (4.5) | 25.2 (2.9) | 34.8 (4.4) |
| SBP, mm Hga | 122 (17) | 127.4 (16) | 128.3 (20) | 135 (19.9) |
| ECG PTFV1, μv∙msa | 2281 (1939) | 2701 (2122) | 2440 (2277) | 2898 (2439) |
| Smoking status, n (%) | ||||
| Current smoker | 521 (17) | 182 (9.9) | 546 (17.4) | 140 (9.5) |
| Former smoker | 1320 (42.9) | 816 (44.3) | 1333 (42.1) | 647 (43.9) |
| Never smoker | 1233 (40.1) | 843 (45.8) | 1288 (40.7) | 687 (46.6) |
| Drinking status, n (%) | ||||
| Current drinker | 1689 (54.9) | 813 (44.2) | 1708 (53.9) | 614 (41.7) |
| Former drinker | 843 (27.4) | 588 (31.9) | 842 (26.6) | 481 (32.6) |
| Never drinker | 542 (17.6) | 440 (23.9) | 617 (19) | 379 (25.7) |
| Aspirin use, n (%) | 1652 (53.7) | 965 (52.4) | 1795 (56.7) | 934 (63.4) |
| Statin use, n (%) | 3090 (10.1) | 197 (10.7) | 345 (10.9) | 213 (14.5) |
| Hypnotic use, n (%) | 890 (29) | 945 (51.3) | 1251 (39.5) | 904 (61.3) |
| DM, n (%) | 370 (12) | 477 (25.9) | 287 (9.1) | 3530 (24.9) |
| MI history, n (%) | 87 (2.8) | 67 (3.6) | 225 (7.1) | 137 (9.3) |
| NT‐proBNP, pg/mLb | 43.7 (28.5–58.6) | 30.8 (17–47.2.4) | 128.4 (92.9–200.5) | 126.8 (91.2–199.6) |
Values correspond to mean (SD) unless otherwise stated. ARIC indicates Atherosclerosis Risk in Communities; BMI, body mass index; DM, diabetes mellitus; MI, myocardial infarction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; PTFV1, P‐wave terminal force in lead V1; SBP, systolic blood pressure.
a
Continuous variable given as mean (SD).
b
Continuous variable given as median (interquartile range).